Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)

This study has been terminated.
(Failure to demonstrate a tolerable dose that had potential for efficacy.)
Sponsor:
Information provided by (Responsible Party):
Kyowa Hakko Kirin Pharma, Inc.
ClinicalTrials.gov Identifier:
NCT00779480
First received: October 22, 2008
Last updated: April 9, 2012
Last verified: April 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2010
  Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)